GlassScriptPhysician profile
Lindsay Goodman
NPI 1093947756
$3,806.15
in general payments reported to CMS, 2019-2025
28 companies · $586 in 2025
The $586 reported for 2025 was more than what 84% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $22.96 · 2021: $663 · 2022: $262 · 2023: $977 · 2024: $982 · 2025: $586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,361 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,360.69 |
| Education | $183.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $645.90 | 2022-2025 | Veozah, Myrbetriq |
| Medical Device Business Services, INC. | $541.50 | 2021 | |
| Mayne Pharma Commercial LLC | $467.08 | 2021-2025 | |
| Abbvie INC. | $346.55 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $291.75 | 2023-2025 | Myfembree, Gemtesa |
| Mimedx Group, INC. | $171.84 | 2024 | |
| Hologic Sales and Service, LLC | $161.48 | 2021-2024 | Aptima, Coolseal Generator |
| Millicent US INC | $153.00 | 2024-2025 | Femlyv, Intrarosa, Femring |
| Gynesonics, INC. | $147.44 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Organon LLC | $146.07 | 2024-2025 | Nexplanon |
| Evofem Biosciences, INC. | $131.11 | 2024-2025 | Phexxi, Solosec, Phexx |
| Boston Scientific Corporation | $113.53 | 2022-2023 | Rezum Generator, Watchman Flx |
| Daiichi Sankyo INC. | $74.07 | 2019-2024 | Injectafer |
| Pfizer INC. | $65.12 | 2019-2023 | |
| Coopersurgical, INC. | $49.77 | 2024-2025 | Paragard T 380a |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $44.34 | 2024 | Twirla |
| Applied Medical Resources Corporation | $37.77 | 2019 | |
| Merck Sharp & Dohme LLC | $28.37 | 2024 | Gardasil, Gardasil 9 |
| Bayer Healthcare Pharmaceuticals INC. | $24.00 | 2025 | |
| Lupin INC. | $22.96 | 2020 | |
| Ironwood Pharmaceuticals, INC | $21.25 | 2024 | |
| Myovant Sciences INC. | $21.20 | 2021 | |
| Duchesnay USA Incorporated | $20.87 | 2019 | |
| Amag Pharmaceuticals, INC. | $18.75 | 2019 | |
| Exeltis, USA INC. | $17.24 | 2023 | Slynd |
| Ardelyx, INC. | $15.28 | 2025 | Ibsrela |
| Avion Pharmaceuticals | $15.05 | 2019 | |
| Ethicon US, LLC | $12.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsay Goodman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.